scispace - formally typeset
G

Girish Venkataraman

Researcher at University of Chicago

Publications -  92
Citations -  2266

Girish Venkataraman is an academic researcher from University of Chicago. The author has contributed to research in topics: Lymphoma & Medicine. The author has an hindex of 23, co-authored 77 publications receiving 1907 citations. Previous affiliations of Girish Venkataraman include Loyola University Medical Center & Loyola University Chicago.

Papers
More filters
Journal ArticleDOI

EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression

TL;DR: EBV-positive mucocutaneous ulcer is proposed as a newly recognized clinicopathologic entity with Hodgkin-like features and a self-limited, indolent course, generally responding well to conservative management.
Journal ArticleDOI

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

TL;DR: Age-related EBV(+) B-cell LPD encompasses a wider disease spectrum than previously recognized and includes both reactive and neoplastic conditions and reduction in the T-cell repertoire may contribute to decreased immune surveillance.
Journal ArticleDOI

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

TL;DR: In patients who had Richter transformation, it is found that the transformed cells were clonal descendants of circulating leukemia cells but continued to undergo evolution and drifts, and transformed lymphoma cells in tissue may acquire a different BTK mutation from that in the CLL leukemia cells.
Journal ArticleDOI

Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.

TL;DR: The close interaction between the HRS-like cells and the rosetting PD-1-positive T cells suggests a possible pathogenetic role in this phenomenon and provides new insights into the abnormal B-cell proliferations that occur in the context of TFH malignancies.
Journal ArticleDOI

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.

TL;DR: Results indicate that PD-L1 alterations identify a unique biological subset of DLBCL in which an endogenous antilymphoma immune response has been activated, and that is associated with responsiveness to PD-1 blockade therapy.